PH-ILD Market Size was valued USD 3 billion in 2024 expected to grow by 2034

The PH-ILD market size was valued at around USD 3 billion in 2024 and is expected to expand at a notable CAGR over the study period (2020–2034). DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the PH-ILD landscape.

In 2024, the PH-ILD market in the U.S. was valued at approximately USD 2 billion and is expected to grow with the introduction of emerging therapies. The combined market size of the EU4 and the UK was around USD 480 million, representing nearly 23% of the total 7MM market revenue, with further growth projected by 2034. Within Europe, the UK led the market with roughly USD 120 million, followed by Germany at about USD 100 million, and Spain at approximately USD 70 million. In Japan, the PH-ILD market was estimated at around USD 285 million in 2024, with anticipated growth over the forecast period (2025–2034).

In 2024, the diagnosed prevalence of PH-ILD in the U.S. showed a slightly higher burden in males, with approximately 42,000 cases compared to 39,000 in females. This gender gap is expected to widen by 2034, indicating potential differences in disease susceptibility or progression. In the EU4 and the UK, around 69,000 individuals were diagnosed with PH-ILD in 2024, reflecting a significant and growing regional disease burden. Within France, CTD-associated PH-ILD had the highest diagnosed prevalence at nearly 4,000 cases, while hypersensitivity pneumonitis had the lowest at just over 500 cases. In Japan, more than 28,000 PH-ILD cases were diagnosed in 2024, with numbers projected to rise by 2034, highlighting an increasing disease burden.

DelveInsight’s report “Pulmonary Hypertension Associated with Interstitial Lung Disease Market Insights, Epidemiology, and Market Forecast-2034,” provides a comprehensive analysis of the Pulmonary Hypertension Associated with Interstitial Lung Disease landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

To Know in detail about the PH-ILD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; PH-ILD Market Forecast

Some of the key facts of the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Report:

• Key PH-ILD Companies: United Therapeutics Corp., Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others
• Key PH-ILD Therapies: TYVASO/TYVASO DPI (treprostinil), TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
• The PH-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Hypertension Associated with Interstitial Lung Disease pipeline products will significantly revolutionize the Pulmonary Hypertension Associated with Interstitial Lung Disease market dynamics.

PH-ILD Overview

PH-ILD (Pulmonary Hypertension associated with Interstitial Lung Disease) is a condition in which high blood pressure develops in the arteries of the lungs (pulmonary hypertension) as a result of underlying interstitial lung diseases (ILDs), such as idiopathic pulmonary fibrosis or connective tissue disease-related ILD.
It occurs when scarring and inflammation in the lung tissue increase resistance in the pulmonary arteries, making it harder for the heart to pump blood through the lungs. This leads to symptoms like shortness of breath, fatigue, and reduced exercise capacity. PH-ILD is a serious, progressive condition that worsens prognosis and requires a multidisciplinary management approach involving both pulmonary and cardiovascular care.

Get a Free sample for the Pulmonary Hypertension Associated with Interstitial Lung Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology

The Pulmonary Hypertension Associated with Interstitial Lung Disease epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Segmentation:

The Pulmonary Hypertension Associated with Interstitial Lung Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of ILD in the 7MM
• Type-specific Diagnosed Prevalent Cases of ILD in the 7MM
• Type-specific Diagnosed Prevalent Cases of PH-ILD in the 7MM
• Total Diagnosed Prevalent Cases of PH-ILD in the 7MM

Download the report to understand which factors are driving PH-ILD epidemiology trends @ Pulmonary Hypertension Associated with Interstitial Lung Disease Epidemiology Forecast

Recent Developments In The PH-ILD Treatment Landscape:

• In September 2025, Pulmovant, a clinical-stage biotech focused on pulmonary disease therapies and a Roivant (Nasdaq: ROIV) company, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation (ODD) to mosliciguat. This novel, once-daily inhaled soluble guanylate cyclase (sGC) activator is under investigation for treating Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD), a progressive, life-threatening condition with a high unmet medical need.
• In June 2025, Halo Biosciences, the developer of HB-1614, reported that a Phase 2a study of the oral therapy candidate indicated the drug is safe and may enhance exercise capacity and quality of life in adults with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The findings were published following the SATURN clinical trial (NCT05128929). 

Pulmonary Hypertension Associated with Interstitial Lung Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Hypertension Associated with Interstitial Lung Disease market or expected to get launched during the study period. The analysis covers Pulmonary Hypertension Associated with Interstitial Lung Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Hypertension Associated with Interstitial Lung Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies and Key Companies

• TYVASO/TYVASO DPI (treprostinil): United Therapeutics Corp.
• Treprostinil Palmitil: Insmed Incorporated
• TPIP: Insmed Incorporated
• INOpulse: Bellerophon Therapeutics
• Inhaled Treprostinil: United Therapeutics
• Riociguat (Adempas, BAY63-2521): Bayer
• Bardoxolone methyl: Biogen

Discover more about therapies set to grab major Pulmonary Hypertension Associated with Interstitial Lung Disease market share @ Pulmonary Hypertension Associated with Interstitial Lung Disease Treatment Landscape

PH-ILD Market Drivers

• The worldwide population and improvement in diagnosis are resulting in a rise in PH prevalence associated with several types of ILDs. This rise in cases is supposed to strengthen the market in the future.
• Treatment demand for PH-ILD is increasing, with a lack of therapies to manage the disease burden. Hence, the market is vast and up for any key player developing a novel therapy.

PH-ILD Market Barriers

• Expected approval of potential therapies can increase market size.
• Lucrative opportunities for market growth in the studied countries, owing to the presence of a large pool of patients suffering from PH-ILD

Scope of the PH-ILD Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Pulmonary Hypertension Associated with Interstitial Lung Disease Companies: United Therapeutics Corp., Insmed Incorporated, Bellerophon Therapeutics, United Therapeutics, Bayer, Biogen, and others
• Key Pulmonary Hypertension Associated with Interstitial Lung Disease Therapies: TYVASO/TYVASO DPI (treprostinil), TPIP, INOpulse, Inhaled Treprostinil, Riociguat (Adempas, BAY63-2521), Bardoxolone methyl, and others
• Pulmonary Hypertension Associated with Interstitial Lung Disease Therapeutic Assessment: Pulmonary Hypertension Associated with Interstitial Lung Disease current marketed and Pulmonary Hypertension Associated with Interstitial Lung Disease emerging therapies
• Pulmonary Hypertension Associated with Interstitial Lung Disease Market Dynamics: Pulmonary Hypertension Associated with Interstitial Lung Disease market drivers and Pulmonary Hypertension Associated with Interstitial Lung Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Pulmonary Hypertension Associated with Interstitial Lung Disease Unmet Needs, KOL’s views, Analyst’s views, Pulmonary Hypertension Associated with Interstitial Lung Disease Market Access and Reimbursement

To know more about Pulmonary Hypertension Associated with Interstitial Lung Disease companies working in the treatment market, visit @ PH-ILD Clinical Trials and Therapeutic Assessment